Estrogen signaling is a therapeutic target for BrCa [5]; identifying pro-metastatic gene expression in different molecular subtypes (hormone receptors) with unique prognostic features may help elucidating new more personalized therapies. The gene discussed is NR4A1; the disease is invasive breast carcinoma.